Univariate analysis of transplant outcomes
| Risk factors . | Two-year CIR . | P . | Two-year LFS . | P . |
|---|---|---|---|---|
| WBCs at diagnosis | ||||
| <30 × 109/L | 18 | .94 | 64 | .48 |
| >30 × 109/L | 18 | 74 | ||
| c-KIT mutations | ||||
| Positive | 9 | .01 | 70 | .12 |
| Negative | 32 | 55 | ||
| Karotype | ||||
| Sole t(8;21) | 18 | .76 | 65 | .85 |
| Additional abnormalities | 20 | 59 | ||
| Courses required to achieve CR | ||||
| 1 | 11 | .02 | 71 | .07 |
| >1 | 29 | 51 | ||
| Time to transplant | ||||
| <6 mo | 34 | .11 | 65 | .53 |
| >6 mo | 16 | 62 | ||
| Donor source | ||||
| HLA-matched sibling | 21 | .42 | 53 | .15 |
| Alternative donor | 16 | 73 | ||
| Stem cell source | ||||
| G-BM + G-PB | 19 | .60 | 63 | .23 |
| G-PB | 26 | 60 | ||
| MRD directly before transplant | ||||
| Reaching MMR | 6 | .08 | 76 | .17 |
| Not reaching MMR | 24 | 60 | ||
| MRD at 1 mo after transplant | ||||
| Reaching MMR | 17 | .05 | 71 | .51 |
| No MMR | 33 | 59 | ||
| MRD at 2 mo after transplant | ||||
| Reaching MMR | 9 | <.001 | 73 | <.001 |
| No MMR | 100 | 0 | ||
| MRD at 3 mo after transplant | ||||
| Reaching MMR | 11 | .0001 | 76 | <.001 |
| No MMR | 46 | 23 | ||
| MRD at the first 3 mo post-HSCT | ||||
| All achieving MMR | 8 | <.001 | 75 | <.001 |
| Not achieving MMR at least once | 56 | 28 | ||
| Acute GVHD | ||||
| With | 15 | .42 | 67 | .75 |
| Without | 21 | 64 | ||
| Transplant center | ||||
| Peking University | 18 | .69 | 65 | .84 |
| Others | 17 | 39 |
| Risk factors . | Two-year CIR . | P . | Two-year LFS . | P . |
|---|---|---|---|---|
| WBCs at diagnosis | ||||
| <30 × 109/L | 18 | .94 | 64 | .48 |
| >30 × 109/L | 18 | 74 | ||
| c-KIT mutations | ||||
| Positive | 9 | .01 | 70 | .12 |
| Negative | 32 | 55 | ||
| Karotype | ||||
| Sole t(8;21) | 18 | .76 | 65 | .85 |
| Additional abnormalities | 20 | 59 | ||
| Courses required to achieve CR | ||||
| 1 | 11 | .02 | 71 | .07 |
| >1 | 29 | 51 | ||
| Time to transplant | ||||
| <6 mo | 34 | .11 | 65 | .53 |
| >6 mo | 16 | 62 | ||
| Donor source | ||||
| HLA-matched sibling | 21 | .42 | 53 | .15 |
| Alternative donor | 16 | 73 | ||
| Stem cell source | ||||
| G-BM + G-PB | 19 | .60 | 63 | .23 |
| G-PB | 26 | 60 | ||
| MRD directly before transplant | ||||
| Reaching MMR | 6 | .08 | 76 | .17 |
| Not reaching MMR | 24 | 60 | ||
| MRD at 1 mo after transplant | ||||
| Reaching MMR | 17 | .05 | 71 | .51 |
| No MMR | 33 | 59 | ||
| MRD at 2 mo after transplant | ||||
| Reaching MMR | 9 | <.001 | 73 | <.001 |
| No MMR | 100 | 0 | ||
| MRD at 3 mo after transplant | ||||
| Reaching MMR | 11 | .0001 | 76 | <.001 |
| No MMR | 46 | 23 | ||
| MRD at the first 3 mo post-HSCT | ||||
| All achieving MMR | 8 | <.001 | 75 | <.001 |
| Not achieving MMR at least once | 56 | 28 | ||
| Acute GVHD | ||||
| With | 15 | .42 | 67 | .75 |
| Without | 21 | 64 | ||
| Transplant center | ||||
| Peking University | 18 | .69 | 65 | .84 |
| Others | 17 | 39 |
G-BM, G-CSF mobilized bone marrow; G-PB, G-CSF mobilized peripheral blood.